BBVA Shareholders Approve €3.4B Final Dividend, Authorize New Share Buyback & €8B CoCo Issuance
summarizeSummary
BBVA's Annual General Meeting approved a substantial final dividend payment and authorized significant capital management initiatives, including a new share buyback program and potential CoCo issuance.
check_boxKey Events
-
Final Dividend Payment Set
Shareholders approved a final dividend of €3,425,381,220 (€0.60 gross per share) for financial year 2025, payable on April 10, 2026. This follows an interim dividend already paid.
-
New Share Buyback Program Authorized
The Board was authorized to acquire own shares for a maximum period of five years, not exceeding 10% of subscribed share capital. This authorization replaces a prior one from March 2022.
-
Capital Reduction Approved
Shareholders approved a reduction of share capital by up to 10% (up to 570,896,870 shares) through the redemption of own shares acquired via buybacks. This aims to enhance earnings per share.
-
€8 Billion CoCo Issuance Authorized
The Board was delegated the power to issue up to €8,000,000,000 in contingently convertible securities (CoCos) over five years, intended to meet regulatory capital requirements.
auto_awesomeAnalysis
The Annual General Shareholders' Meeting resolutions outline a robust capital management strategy for BBVA. The approval of a substantial final dividend provides immediate capital return to shareholders. Furthermore, the authorization for a new share buyback program, allowing for repurchases of up to 10% of share capital, coupled with the capital reduction approval, signals a strong commitment to enhancing shareholder value through reduced share count and improved earnings per share. The authorization to issue up to €8 billion in contingently convertible securities (CoCos) provides the bank with significant flexibility to manage its regulatory capital requirements over the next five years.
At the time of this filing, BBVA was trading at $20.49 on NYSE in the Finance sector, with a market capitalization of approximately $118.2B. The 52-week trading range was $11.59 to $26.20. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.